Patent application EP16205331A (EP), filed 2016-12-20
Publication number: EP3184543A2
Title: IMMUNOPOTENTIATOR CONTAINING ANTI-ANG2 ANTIBODY
Abstract: Provided is a method of potentiating immunity or preventing and/or treating an immune-related disease comprising administering an anti-Ang2 antibody or an antigen-binding fragment thereof to a subject in need thereof.
IPC codes: A61K  39/    00            A I
C07K  16/    22            A I
C07K  16/    26            A I
Claims: number: 1
text: An anti-Ang2 antibody or an antigen-binding fragment thereof for use in potentiating immunity, wherein the anti-Ang2 antibody or antigen-binding fragment thereof binds to Ang2 and forms a complex with Tie2 receptor through Ang2.
number: 2
text: The anti-Ang2 antibody or an antigen-binding fragment thereof for use of claim 1, wherein the anti-Ang2 antibody or antigen-binding fragment thereof binds to Q418, P419, a combination of Q418 and P419, or 2 to 20 consecutive acid residues of human Ang2 of SEQ ID NO: 11, including Q418, P419, a combination of Q418 or P419.
number: 3
text: The anti-Ang2 antibody or an antigen-binding fragment thereof for use of claim 1 or 2, wherein the anti-Ang2 antibody or antigen-binding fragment thereof comprises:
number: 4
text: The anti-Ang2 antibody or an antigen-binding fragment thereof for use of claim 3, wherein the anti-Ang2 antibody or antigen-binding fragment thereof comprises:
number: 5
text: The anti-Ang2 antibody or an antigen-binding fragment thereof for use of claim 4, wherein the anti-Ang2 antibody or antigen-binding fragment thereof comprises:
number: 6
text: The anti-Ang2 antibody or an antigen-binding fragment thereof for use of any one of claims 1 to 5, wherein the anti-Ang2 antibody or antigen-binding fragment thereof is a mouse antibody, a chimeric antibody, or a humanized antibody.
number: 7
text: The anti-Ang2 antibody or an antigen-binding fragment thereof for use of any one of claims 1 to 6, wherein the anti-Ang2 antibody or an antigen-binding fragment thereof is used in 1) improvement or increase in resistance to thymus involution, thymic function, the number of T cells, or production of hematopoietic stem cells, or 2) augmentation or recovery of T cell functions, and the like
number: 8
text: An anti-Ang2 antibody or an antigen-binding fragment thereof for use in preventing or treating an immune-related disease, comprising administering an anti-Ang2 antibody or an antigen-binding fragment thereof to a subject in need of preventing or treating an immune-related disease, wherein the anti-Ang2 antibody or antigen-binding fragment thereof binds to Ang2 and forms a complex with Tie2 receptor through Ang2.
number: 9
text: The anti-Ang2 antibody or an antigen-binding fragment thereof for use of claim 8, wherein the anti-Ang2 antibody or antigen-binding fragment thereof binds to Q418, P419, a combination of Q418 and P419, or 2 to 20 consecutive acid residues of human Ang2 of SEQ ID NO: 11, including Q418, P419, a combination of Q418 or P419.
number: 10
text: The anti-Ang2 antibody or an antigen-binding fragment thereof for use of claim 8 or 9, wherein the anti-Ang2 antibody or antigen-binding fragment thereof comprises:
number: 11
text: The anti-Ang2 antibody or an antigen-binding fragment thereof for use of claim 10, wherein the anti-Ang2 antibody or antigen-binding fragment thereof comprises:
number: 12
text: The anti-Ang2 antibody or an antigen-binding fragment thereof for use of claim 11, wherein the anti-Ang2 antibody or antigen-binding fragment thereof comprises:
number: 13
text: The anti-Ang2 antibody or an antigen-binding fragment thereof for use of any one of claims 8 to 12, wherein the anti-Ang2 antibody or antigen-binding fragment thereof is a mouse antibody, a chimeric antibody, or a humanized antibody.
number: 14
text: The anti-Ang2 antibody or an antigen-binding fragment thereof for use of any one of claims 8 to 13, wherein the immune-related disease is acquired immune deficiency syndrome or an autoimmune disease.
Office action: search_report, dated 2017-06-28
Rejection reasons: inventive_step_epc_56
Prior art cited: ref_id: - SCHWABER, J; COHEN, E. P.: "Human x Mouse Somatic Cell Hybrid Clones Secreting Immunoglobulins of Both Parental Types", NATURE, vol. 244, 1973, pages 444 - 447
ref_type: npl
severity: background
ref_id: US2015337033
ref_type: patent
severity: obviousness
ref_id: - ITALIA GRENGA ET AL, "Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack", JOURNAL FOR IMMUNOTHERAPY OF CANCER, (20151117), vol. 3, no. 1, doi:10.1186/s40425-015-0096-7, XP055357747 [Y] 1-7 * abstract *
ref_type: npl
severity: obviousness
ref_id: - S. B. COFFELT ET AL, "Angiopoietin 2 Stimulates TIE2-Expressing Monocytes To Suppress T Cell Activation and To Promote Regulatory T Cell Expansion", THE JOURNAL OF IMMUNOLOGY, US, (20110302), vol. 186, no. 7, doi:10.4049/jimmunol.1002802, ISSN 0022-1767, pages 4183 - 4190, XP055357255 [Y] 1-7 * abstract *
ref_type: npl
severity: obviousness
ref_id: - KUEMPERS P ET AL, "The Tie2 receptor antagonist angiopoietin 2 facilitates vascular inflammation in systemic lupus erythematosus", ANNALS OF THE RHEUMATIC DISE, BRITISH MEDICAL ASSOCIATION, GB, vol. 68, no. 10, doi:10.1136/ARD.2008.094664, ISSN 0003-4967, (20091001), pages 1638 - 1643, (20081017), XP008114161 [Y] 8-14 * abstract * * Discussion *
ref_type: npl
severity: obviousness
ref_id: - ALEXANDER SCHOLZ ET AL, "Angiopoietin-2: a multifaceted cytokine that functions in both angiogenesis and inflammation : Angiopoietin-2 and inflammation", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, US, (20150313), vol. 1347, no. 1, doi:10.1111/nyas.12726, ISSN 0077-8923, pages 45 - 51, XP055388983 [Y] 8-14 * page  47, column  r, paragraph  last *
ref_type: npl
severity: obviousness
ref_id: - NICTÉ FIGUEROA-VEGA ET AL, "Tie-2 Is Overexpressed by Monocytes in Autoimmune Thyroid Disorders and Participates in Their Recruitment to the Thyroid Gland", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, US, (20090701), vol. 94, no. 7, doi:10.1210/jc.2009-0220, ISSN 0021-972X, pages 2626 - 2633, XP055388843 [Y] 8-14 * Discussion *
ref_type: npl
severity: obviousness
ref_id: - LAWRENCE F. BROWN ET AL, "Expression of Tie1, Tie2, and Angiopoietins 1, 2, and 4 in Kaposi's Sarcoma and Cutaneous Angiosarcoma", AMERICAN JOURNAL OF PATHOLOGY., US, (20000601), vol. 156, no. 6, doi:10.1016/S0002-9440(10)65088-2, ISSN 0002-9440, pages 2179 - 2183, XP055388979 [Y] 8-14 * abstract *
ref_type: npl
severity: obviousness
Final disposition: pending (2017-06-28)